Literature DB >> 15623630

Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.

Qiwei Yang1, Peter Zage, David Kagan, Yufeng Tian, Roopa Seshadri, Helen R Salwen, Shuqing Liu, Alexandre Chlenski, Susan L Cohn.   

Abstract

PURPOSE: To investigate the prevalence and potential clinical significance of epigenetic aberrations in neuroblastoma (NB). EXPERIMENTAL
DESIGN: The methylation status of 11 genes that are frequently epigenetically inactivated in adult cancers was assayed in 13 NB cell lines. The prevalence of RASSF1A and TSP-1 methylation was also analyzed in 56 NBs and 5 ganglioneuromas by methylation-specific PCR. Associations between the methylation status of RASSF1A and TSP-1 and patient age, tumor stage, tumor MYCN status, and patient survival were evaluated.
RESULTS: Epigenetic changes were detected in all 13 NB cell lines, although the pattern of gene methylation varied. The putative tumor suppressor gene RASSF1A was methylated in all 13 cell lines, and TSP-1 and CASP8 were methylated in 11 of 13 cell lines. Epigenetic changes of DAPK and FAS were detected in only small numbers of cell lines, whereas none of the cell lines had methylation of p16, p21, p73, RAR-beta2, SPARC, or TIMP-3. RASSF1A was also methylated in 70% of the primary NB tumors tested, and TSP-1 methylation was detected in 55% of the tumors. RASSF1A methylation was significantly associated with age >1 year (P < 0.01), high-risk disease (P < 0.016), and poor survival (P < 0.001). In contrast, no association between TSP-1 methylation and prognostic factors or survival was observed.
CONCLUSIONS: Our results suggest that epigenetic inactivation of RASSF1A may contribute to the clinically aggressive phenotype of high-risk NB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623630     DOI: 10.1158/1078-0432.CCR-04-1331

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma.

Authors:  Kelly R Ostler; Qiwei Yang; Timothy J Looney; Li Zhang; Aparna Vasanthakumar; Yufeng Tian; Masha Kocherginsky; Stacey L Raimondi; Jessica G DeMaio; Helen R Salwen; Song Gu; Alexandre Chlenski; Arlene Naranjo; Amy Gill; Radhika Peddinti; Bruce T Lahn; Susan L Cohn; Lucy A Godley
Journal:  Cancer Res       Date:  2012-07-18       Impact factor: 12.701

Review 2.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

3.  The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis.

Authors:  L van der Weyden; K K Tachibana; M A Gonzalez; D J Adams; B L Ng; R Petty; A R Venkitaraman; M J Arends; A Bradley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

4.  Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells.

Authors:  Sarandeep S S Boyanapalli; Wenji Li; Francisco Fuentes; Yue Guo; Christina N Ramirez; Ximena-Parades Gonzalez; Douglas Pung; Ah-Ng Tony Kong
Journal:  Pharmacol Res       Date:  2016-11-03       Impact factor: 7.658

5.  Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.

Authors:  Chandra M Das; Peter E Zage; Pete Taylor; Dolly Aguilera; Johannes E A Wolff; Dean Lee; Vidya Gopalakrishnan
Journal:  Eur J Cancer       Date:  2010-10       Impact factor: 9.162

6.  SPARC ameliorates ovarian cancer-associated inflammation.

Authors:  Neveen A Said; Ahmed A Elmarakby; John D Imig; David J Fulton; Kouros Motamed
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.

Authors:  Qiwei Yang; Yufeng Tian; Kelly R Ostler; Alexandre Chlenski; Lisa J Guerrero; Helen R Salwen; Lucy A Godley; Susan L Cohn
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

8.  RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.

Authors:  Shohei Honda; Hisayuki Miyagi; Hiromu Suzuki; Masashi Minato; Masayuki Haruta; Yasuhiko Kaneko; Kanako C Hatanaka; Eiso Hiyama; Takehiko Kamijo; Tadao Okada; Akinobu Taketomi
Journal:  Pediatr Surg Int       Date:  2013-11       Impact factor: 1.827

9.  Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.

Authors:  Song Gu; Yufeng Tian; Alexandre Chlenski; Helen R Salwen; Ziyan Lu; J Usha Raj; Qiwei Yang
Journal:  Anticancer Drugs       Date:  2012-11       Impact factor: 2.248

10.  Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Authors:  Ziyan Lu; Yufeng Tian; Helen R Salwen; Alexandre Chlenski; Lucy A Godley; J Usha Raj; Qiwei Yang
Journal:  Anticancer Drugs       Date:  2013-06       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.